Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus  Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more  

February 4, 2021 12:36 AM UTC

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company, and existing investor Vivo Capital, which purchased 18.9 million shares to bring its stake to 8.2%. The deal came two days after Hillhouse invested HK$1.3 billion in new shares of CNS and cancer play Luye Pharma Group Ltd. (HKEX:2186) and bought existing shares from a selling stakeholder to obtain a 15.6% stake in the company; the firm’s two deals with Luye totaled HK$2.4 billion.

Accelerated approval for Tepmetko for NSCLC with METex14
FDA granted accelerated approval to Tepmetko tepotinib from Merck KGaA (Xetra:MRK) under its Real-Time Oncology Review pilot to treat metastatic non-small cell lung cancer patients with mesenchymal-epithelial transition exon 14 (METex14) skipping alterations. The once-daily oral c-MET inhibitor is already approved in Japan. The review was conducted under Project Orbis, with FDA collaborating with Health Canada, Australia’s Therapeutic Goods Administration and Swissmedic...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article